Turnstone Biologics Corp. Files 8-K with Key Corporate Changes
| Field | Detail |
|---|---|
| Company | Turnstone Biologics Corp. |
| Form Type | 8-K |
| Filed Date | Jun 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, material-agreement, officer-changes
TL;DR
Turnstone Biologics 8-K: New deals, departures, and exec changes filed June 26.
AI Summary
Turnstone Biologics Corp. announced on June 26, 2025, the entry into a material definitive agreement and the termination of another. The company also reported the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with compensatory arrangements for these officers. Additionally, a Regulation FD Disclosure was made, and financial statements and exhibits were filed.
Why It Matters
This filing indicates significant corporate governance and contractual changes at Turnstone Biologics, which could impact its strategic direction and operational agreements.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, terminations, and changes in officers/directors, which can introduce uncertainty and potential risks.
Key Players & Entities
- Turnstone Biologics Corp. (company) — Registrant
- June 26, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41747 (commission_file_number) — SEC File Number
- 9310 Athena Circle, Suite 3000 (address) — Business and Mail Address
- La Jolla, California 92037 (address) — Business and Mail Address
FAQ
What specific material definitive agreements were entered into by Turnstone Biologics?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
What material definitive agreements were terminated by Turnstone Biologics?
The filing states the termination of a material definitive agreement, but the specifics of the terminated agreement are not detailed in the provided text.
Were there any changes in the board of directors or executive officers at Turnstone Biologics?
Yes, the filing reports the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
What is the primary business of Turnstone Biologics Corp.?
Turnstone Biologics Corp. is in the business of BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES), with a Standard Industrial Classification code of 2836.
When was this 8-K filing submitted?
This 8-K filing was submitted on June 27, 2025, reporting events as of June 26, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 regarding Turnstone Biologics Corp..